News
-
ADmit Therapeutics Obtains CLIA Certification, Opening Doors to the U.S. Healthcare Market
Barcelona (Spain), December 4, 2025. ADmit Therapeutics today announced that it has obtained the CLIA (Clinical Laboratory Improvement Amendments) Certificate. This accreditation, granted by the US Centers for Medicare & Medicaid Services (CMS), confirms compliance with the most stringent standards for analytical quality and reliability. Obtaining CLIA certification is a crucial milestone that transforms ADmit Therapeutics into a
-
ADmit Therapeutics Presents Innovation in Seville: The MAP-AD® Test and New Data on Alzheimer’s Prediction
The company will attend the SEN Annual Meeting with its MAP-AD® test, recently certified with the CE-IVDR mark, highlighting breakthroughs in early Alzheimer’s disease dementia prognosis. Barcelona (Spain), November 14, 2025 – ADmit Therapeutics, a leading company in the diagnosis of neurodegenerative diseases, has confirmed its participation in the upcoming Annual Meeting of the Spanish Society of Neurology
-
ADmit Therapeutics to showcase European innovation at MEDICA 2025
Barcelona (Spain), November 13,2025. We are proud to announce that our company has been selected to participate in MEDICA 2025, taking place from 17–20 November 2025 in Düsseldorf, Germany. ADmit Therapeutis will be at the EIC Pavilion at Messe Düsseldorf – Hall 15, Booth 15B41. Our company is one of the 15 SMEs, start-ups, and
-
ADmit Therapeutics was named Best Startup 2025 at the WA4STEAM Awards
Barcelona, October 21, 2025 – ADmit Therapeutics was named Best Startup 2025 at the WA4STEAM Awards celebrated in Madrid last Friday, October 17th. This is the second edition of the WA4STEAM Awards, which recognizes, promotes, and gives greater visibility to women leaders in the entrepreneurial ecosystem (founders, startups, and ecosystem members) who are becoming true
-
The MAP-AD® Test obtains the CE-IVDR mark, the first prognostic test for Alzheimer’s disease dementia
Barcelona (Spain,) September 19, 2025. ADmit Therapeutics S.L. announced today that its disruptive blood test for the prognosis of Alzheimer’s dementia, the MAP-AD® Test, has received the CE Mark under the In Vitro Diagnostic Regulation (IVDR, 2017/746). This certification confirms that the test complies with the European Union’s strict safety and performance standards, a significant milestone for
-
ADmit Therapeutics publishes a key study on a new blood-based biomarker that predicts the progression to Alzheimer’s dementia
Barcelona, September 19, 2025– ADmit Therapeutics S.L. today announced the publication of a blood biomarker in the journal iScience (Cell Press). The study details the fundamental research that led to the development of the Test MAP-AD®, a prognostic solution based on mitochondrial DNA methylation levels in blood that predicts progression to Alzheimer’s dementia in patients with Mild Cognitive Impairment (MCI). The
